FINANCIAL CHRONICLE™
Dear Reader,

Registration with the Sri Lanka FINANCIAL CHRONICLE™️ would enable you to enjoy an array of other services such as Member Rankings, User Groups, Own Posts & Profile, Exclusive Research, Live Chat Box etc..

All information contained in this forum is subject to Disclaimer Notice published.


Thank You
FINANCIAL CHRONICLE™️
www.srilankachronicle.com


Join the forum, it's quick and easy

FINANCIAL CHRONICLE™
Dear Reader,

Registration with the Sri Lanka FINANCIAL CHRONICLE™️ would enable you to enjoy an array of other services such as Member Rankings, User Groups, Own Posts & Profile, Exclusive Research, Live Chat Box etc..

All information contained in this forum is subject to Disclaimer Notice published.


Thank You
FINANCIAL CHRONICLE™️
www.srilankachronicle.com
FINANCIAL CHRONICLE™
Would you like to react to this message? Create an account in a few clicks or log in to continue.

Encyclopedia of Latest news, reviews, discussions and analysis of stock market and investment opportunities in Sri Lanka


Submit PostSubmit Post
ශ්‍රී ලංකා මූල්‍ය වංශකථාව - සිංහල
Submit Post



Latest topics

» GLAS will be winner with Super Gain.
by ADVENTUS Today at 6:10 pm

» Ban of chemical fertilizers is a great news
by celtic tiger Today at 6:07 pm

» DIPPED PRODUCTS PLC (DIPD.N0000)
by ADVENTUS Today at 4:37 pm

» FUTURE of BROWNS INVESTMENT PLC (BIL)
by EPS Today at 7:56 am

» Sri Lanka Bonds Go From Asia’s Worst to Best After China Loan
by dayandacool Yesterday at 11:31 pm

» CSE listed companies...Failed or collapsed
by High-flyer Yesterday at 9:14 pm

» L B FINANCE PLC (LFIN.N0000)
by kanishkaecomm Yesterday at 5:17 pm

» කොටස් වෙළඳපොළ2020
by කොටස් වෙළඳපොළ2020 Yesterday at 11:52 am

» 14 May onwards -Road Clear to Enter one of the Asias Most Undervalued Stock Market
by kalu351 Yesterday at 6:34 am

» Plantation Sector
by කොටස් වෙළඳපොළ2020 Fri May 14, 2021 10:13 pm

» Company Financials or Group Financials?
by ronstyn53 Fri May 14, 2021 8:07 pm

» Banking Sector Analysis
by ADVENTUS Fri May 14, 2021 7:34 pm

» CHEVRON LUBRICANTS LANKA PLC ((LLUB.N0000)
by Bakkabwoi Fri May 14, 2021 5:24 pm

» Grain Elevators Earnings Review With Q1 Results
by EquityChamp Fri May 14, 2021 10:11 am

» What will happen tomorrow?
by Lakshman wijayawardhana Fri May 14, 2021 9:57 am

» Most Undervalued Shares
by Lakshman wijayawardhana Fri May 14, 2021 9:54 am

» Future of Talawakelle Plantation PLC
by කොටස් වෙළඳපොළ2020 Fri May 14, 2021 5:02 am

» NEVER GIVE UP BECAUSE: Stock market for beginners
by Asoka Samarakone Wed May 12, 2021 9:37 pm

» Make it your goal to stay positive in a negative market
by reyaz Wed May 12, 2021 9:01 pm

» Daily Foreign Transactions
by Pradeep90 Wed May 12, 2021 8:32 pm

EXPERT CHRONICLE™

ECONOMIC CHRONICLE

GROSS DOMESTIC PRODUCT (GDP)


CHRONICLE™ YouTube

CHRONICLE™ NEWS PRODUCTS

FINANCIAL CHRONICLE™

Views & Reviews, Analysis, Evaluations, Discussions, Gossip and Hot Tips relating to Sri Lankan companies listed on the Colombo Stock Exchange (CSE)
Contribute




DAILY CHRONICLE™

Latest news and articles published in Newspapers, Websites, Blogs and other online news sites relating to business and investments in Sri Lanka
Contribute



ECONOMIC CHRONICLE™

This is a section that provide news, views, analysis, predications relating to Political and Socio-Economic factors and how such activities affect the Stock Market and other economic activity of the Country.

Contribute




EXPERT CHRONICLE™

This is an exclusive section for Expert Articles which will help member to share knowledge through comments and responses of the members. All members are allowed to reply and make comments to these articles.

Contribute


Submit Post


CHRONICLE™ YouTube

Youtube Videos and other visual presentations relating Stock market and other investment advise submitted by members or other contributors.

Contribute


Submit Post


කොළඔ කොටස් වෙළඳපොළේ වංශකථාව
කොළඔ කොටස් වෙළඳපොළේ ලැයිස්තුගත සමාගම් කොටස් ගැන තොරතුරු¸විශ්ලේෂණ¸සාකච්ඡා¸ කටකතා¸රසකතා යන සියල්ල අපේම සිංහලෙන් කතා කළ හැකි ‘කතා මණ්ඩපය’

Contribute

Twitter Feeds
POPULAR COMPANIES
A

ABANS ELECTRICALS PLC

ACCESS ENGINEERING PLC Hot

ACL CABLES PLC

ACL PLASTICS PLC

ACME PRINTING & PACKAGING PLC

AGSTAR PLC

AITKEN SPENCE HOTEL HOLDINGS PLC

AITKEN SPENCE PLC

ANILANA HOTELS AND PROPERTIES PLC

ARPICO INSURANCE PLC

ASIA ASSET FINANCE PLC

ASIA CAPITAL PLC

B

BAIRAHA FARMS PLC

BALANGODA PLANTATIONS PLC

BIMPUTH FINANCE PLC

BLUE DIAMONDS JEWELLERY WORLDWIDE PLC

B P P L HOLDINGS PLC

BROWNS BEACH HOTELS PLC

BROWNS INVESTMENTS PLC

C

CARGO BOAT DEVELOPMENT COMPANY PLC

CENTRAL INDUSTRIES PLC

CEYLON COLD STORES PLC

CEYLON GRAIN ELEVATORS PLC Hot

CEYLON TEA BROKERS PLC

CEYLON TOBACCO COMPANY PLC

CHEVRON LUBRICANTS LANKA PLC

COLOMBO FORT LAND & BUILDING PLC

COMMERCIAL BANK OF CEYLON PLC

CITRUS LEISURE PLC Hot

COMMERCIAL CREDIT AND FINANCE PLC

D

DANKOTUWA PORCELAIN PLC

DFCC BANK PLC

DIALOG AXIATA PLC

DIALOG FINANCE PLC

DIPPED PRODUCTS PLC

DISTILLERIES COMPANY OF SRI LANKA PLC

DUNAMIS CAPITAL PLC

E

EAST WEST PROPERTIES PLC Hot

EASTERN MERCHANTS PLC

EXPOLANKA HOLDINGS PLC

E-CHANNELLING PLC

F

FIRST CAPITAL HOLDINGS PLC

G

GALADARI HOTELS (LANKA) PLC

GUARDIAN CAPITAL PARTNERS PLC

H

HATTON NATIONAL BANK PLC

HAYLEYS PLC

HAYLEYS FABRIC PLC

HAYLEYS FIBRE PLC Hot

HEMAS HOLDINGS PLC

HIKKADUWA BEACH RESORT PLC

HNB ASSURANCE PLC

HVA FOODS PLC

J

JANASHAKTHI INSURANCE COMPANY PLC

JOHN KEELLS HOLDINGS PLC Hot

JOHN KEELLS HOTELS PLC

L

LANKA ASHOK LEYLAND PLC

LANKA IOC PLC

LANKEM CEYLON PLC

LANKEM DEVELOPMENTS PLC

LAUGFS GAS PLC

LAUGFS POWER LIMITED

LOLC FINANCE PLC

LOLC HOLDINGS PLC

LUCKY LANKA MILK PROCESSING COMPANY PLC

M

MELSTACORP PLC

N

NATIONAL DEVELOPMENT BANK PLC

NATION LANKA FINANCE PLC

NESTLE LANKA PLC

O

ORIENT FINANCE PLC

OVERSEAS REALTY (CEYLON) PLC

P

PANASIAN POWER PLC

PEOPLE'S LEASING & FINANCE PLC

PIRAMAL GLASS CEYLON PLC

PRIME FINANCE PLC

R

RAIGAM WAYAMBA SALTERNS PLC

RENUKA AGRI FOODS PLC

RENUKA CAPITAL PLC

RENUKA HOLDINGS PLC

RICHARD PIERIS AND COMPANY PLC

RICHARD PIERIS EXPORTS PLC Hot

ROYAL CERAMICS PLC

S

SAMPATH BANK PLC

SEYLAN BANK PLC

SIERRA CABLES PLC

SINGHE HOSPITALS PLC Hot

SMB LEASING PLC

SOFTLOGIC HOLDINGS PLC

SOFTLOGIC LIFE INSURANCE PLC

SRI LANKA TELECOM PLC

SWISSTEK (CEYLON) PLC Hot

T

TEEJAY LANKA PLC

TESS AGRO PLC

THREE ACRE FARMS PLC

TOKYO CEMENT COMPANY (LANKA) PLC Hot

U

UNION BANK OF COLOMBO PLC

V

VALLIBEL FINANCE PLC

VALLIBEL ONE PLC Hot

VALLIBEL POWER ERATHNA PLC

W

WASKADUWA BEACH RESORT PLC


You are not connected. Please login or register

FINANCIAL CHRONICLE™ » FINANCIAL CHRONICLE™ » Good News regarding Dengue

Good News regarding Dengue

Go down  Message [Page 1 of 1]

1Good News regarding Dengue  Empty Good News regarding Dengue Wed Jul 19, 2017 1:30 pm

Neluka Karannagoda


Manager - Equity Analytics
Manager - Equity Analytics
A vaccine called Takeda or TAK-003 is succsussfull against the dengue fever. Good news is it is test in Sri Lanka also and up to now 3000 persons vaccinated to test it in Sri Lanka. Now the phase 3 of its test is going on and 1st and 2nd phases are very successful according to the Takeda Company. As soon as they got the results of the 3rd phase or the final phase they will get the License to this vaccine and hopefully it will come to Sri Lanka in around March 2018.


Osaka, Japan, March 30, 2017 – Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that data from a 6-month interim analysis* of the ongoing DEN-204 trial of its live-attenuated tetravalent dengue vaccine candidate, TAK-003 (also referred to as TDV), have been published in The Lancet Infectious Diseases.[1]
The trial investigated the safety and immunogenicity of TAK-003 in 1,794 participants ages two through 17 living in dengue-endemic areas (the Dominican Republic, Panama and the Philippines). At the time of the analysis, participants had either received one dose of TAK-003, two doses of TAK-003 administered three months apart, or a placebo.
The published data showed that TAK-003 elicited a broad antibody response against all four dengue virus types (called serotypes), regardless of previous exposure to the dengue virus.[1] The increased presence of antibodies in the blood against the four serotypes (seropositivity) ranged between 87-100% by Month 1 and was sustained at Month 6 (85-100%), in both the one-dose and two-dose groups.[1] This analysis also showed that, in participants who were not previously exposed to dengue infection (seronegative) before vaccination, seropositivity rates against dengue virus types 3 and 4 were improved after a second dose of vaccine.[1] For this reason, a two-dose regimen, administered three months apart, was selected for Takeda’s ongoing global pivotal Phase 3 efficacy trial.[2]                           
This analysis also showed that TAK-003 was safe and well-tolerated in children and adolescents in terms of solicited local reactions and systemic adverse events; no vaccine-related serious adverse events (SAEs) occurred, and the expected immunological responses to the vaccine and associated signs and symptoms (reactogenicity) was limited.[1] The number of adverse events reported were similar or lower than those reported for other live attenuated vaccines, and the safety profile was consistent with that observed in earlier Phase 1 and 2 studies of the vaccine candidate.[1]

Dengue fever is a painful, debilitating mosquito-borne disease caused by any one of four closely related virus serotypes.[3] Forty percent of the world lives under the threat of dengue, which can affect people of all ages and is a leading cause of serious illness and death among children throughout the world.[4],[5]
“The levels of immunogenicity induced by TAK-003 against all four dengue serotypes, even in seronegative participants, are encouraging because seropositivity after vaccination may be an important measure of vaccine performance,” said Xavier Sáez-Llorens, M.D., primary author of The Lancet Infectious Diseases publication and Head of Infectious Diseases and Director of Clinical Research at the Panama Children’s Hospital. “Infection with one dengue serotype makes subsequent infection with a different serotype a major risk factor for severe disease, hence the need for a safe and effective vaccine that simultaneously protects against all four serotypes.[6] The durability of these antibody responses and the contribution of cell-mediated immune responses to disease protection warrant further study.”
“These and other Phase 1 and Phase 2 safety and immunogenicity data support continued development of this important vaccine candidate,”[1],[7],[8] said Derek Wallace, M.B.B.S., Global Dengue Program Head at Takeda. “We look forward to ongoing studies, which will assess the candidate vaccine’s ability to provide protection against all four dengue serotypes in recipients of all ages, whether or not they have been previously exposed to dengue.”
In September 2016, Takeda initiated its pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES). The randomized, double-blind, placebo-controlled, multi-center trial is designed to investigate the efficacy, safety and immunogenicity of Takeda’s dengue vaccine candidate, administered in two doses, three months apart, in dengue-endemic countries in Latin America and Asia.[2] Evaluation of the trial’s primary endpoint, vaccine protection against virologically-confirmed dengue of any severity caused by any serotype regardless of previous exposure, is expected in 2018.[2] Secondary endpoints include vaccine efficacy in preventing dengue induced by each serotype, vaccine efficacy in preventing dengue caused by any serotype regardless of participants’ baseline status, vaccine efficacy in preventing hospitalization due to dengue, and vaccine efficacy in preventing severe dengue induced by any serotype.[2] 

*An interim data analysis is a pre-planned evaluation of data from an ongoing trial before final data collection. 
About the Phase 2 DEN-204 Study
The Phase 2 DEN-204 study is a randomized, double-blind, placebo-controlled, multi-center trial designed to assess the safety and immunogenicity of either a one- or two-dose schedule of TAK-003 in 1,794 healthy participants living in dengue-endemic areas (the Dominican Republic, Panama and the Philippines).[1] Participants were ages two through 17 and were randomized to one of four groups, two of which received a one-dose vaccine schedule, one of which received a two-dose vaccine schedule administered three months apart, and one which received placebo, by the 6 month interim analysis timepoint.[1] The primary endpoint of this interim analysis was geometric mean titers (GMTs) of neutralizing antibodies (an indicator of immune response) to the four dengue virus serotypes (DENV-1-4) in the per protocol immunogenicity subset (PPS), a group of participants who had no major protocol violations and for whom valid pre- and post-dosing blood samples were available and immunogenicity was evaluated, at months one, three, and six.1 Secondary endpoints included occurrence of serious adverse events (SAEs), seropositivity rates (percentage of participants who developed antibodies), and adverse events (AEs) in the immunogenicity subset.[1] 
About Takeda’s Dengue Vaccine Candidate (TAK-003)
Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus (DENV-2), which provides the genetic ‘backbone’ for all four vaccine viruses.[9]Takeda’s dengue vaccine is being developed to support the protection of populations and individuals at risk for dengue across geographies whether or not they have had previous exposure to dengue virus, including children and adults, travelers and those living in endemic areas.
Phase 1 data has been published in the Journal of Infectious Diseases,Lancet Infectious Diseases and Vaccine. Interim results of DEN-203, a Phase 2, placebo-controlled, multi-center, age-descending trial, were presented during the American Society of Tropical Medicine and Hygiene (ASTMH) meeting in October 2015.[8] Interim results of DEN-204 were also presented during the 5th Annual Pan-American Dengue Research Network Meeting in May 2016 and ASTMH in November 2016.[10],[11] 
Takeda’s Commitment to Vaccines
Vaccines prevent more than two million deaths each year and have transformed global public health.[12] For 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, Zika, norovirus and polio. Our team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs.

Back to top  Message [Page 1 of 1]

Permissions in this forum:
You cannot reply to topics in this forum